BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 29383520)

  • 1. The prognostic and predictive value of vascular response parameters measured by dynamic contrast-enhanced-CT, -MRI and -US in patients with metastatic renal cell carcinoma receiving sunitinib.
    Hudson JM; Bailey C; Atri M; Stanisz G; Milot L; Williams R; Kiss A; Burns PN; Bjarnason GA
    Eur Radiol; 2018 Jun; 28(6):2281-2290. PubMed ID: 29383520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Metastatic renal cell carcinoma treated with sunitinib: early evaluation of treatment response using dynamic contrast-enhanced ultrasonography.
    Lassau N; Koscielny S; Albiges L; Chami L; Benatsou B; Chebil M; Roche A; Escudier BJ
    Clin Cancer Res; 2010 Feb; 16(4):1216-25. PubMed ID: 20145174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sequential FDG-PET/CT as a biomarker of response to Sunitinib in metastatic clear cell renal cancer.
    Kayani I; Avril N; Bomanji J; Chowdhury S; Rockall A; Sahdev A; Nathan P; Wilson P; Shamash J; Sharpe K; Lim L; Dickson J; Ell P; Reynolds A; Powles T
    Clin Cancer Res; 2011 Sep; 17(18):6021-8. PubMed ID: 21742806
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CT texture analysis: a potential tool for prediction of survival in patients with metastatic clear cell carcinoma treated with sunitinib.
    Haider MA; Vosough A; Khalvati F; Kiss A; Ganeshan B; Bjarnason GA
    Cancer Imaging; 2017 Jan; 17(1):4. PubMed ID: 28114978
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Revised Choi imaging criteria correlate with clinical outcomes in patients with metastatic renal cell carcinoma treated with sunitinib.
    Thian Y; Gutzeit A; Koh DM; Fisher R; Lote H; Larkin J; Sohaib A
    Radiology; 2014 Nov; 273(2):452-61. PubMed ID: 24869795
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quantifying vascular heterogeneity using microbubble disruption-replenishment kinetics in patients with renal cell cancer.
    Hudson JM; Williams R; Karshafian R; Milot L; Atri M; Burns PN; Bjarnason GA
    Invest Radiol; 2014 Feb; 49(2):116-23. PubMed ID: 24220251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Value of Quantitative Metabolic Metrics on Baseline Pre-Sunitinib FDG PET/CT in Advanced Renal Cell Carcinoma.
    Minamimoto R; Barkhodari A; Harshman L; Srinivas S; Quon A
    PLoS One; 2016; 11(4):e0153321. PubMed ID: 27123976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Comparison of efficacy between sorafenib and sunitinib as first-line therapy for metastatic renal cell carcinoma and analyze prognostic factors for survival].
    Cai W; Yuan YC; Li MY; Kong W; Dong BJ; Chen YH; Zhang J; Xue W; Huang YR; Zhou LX; Huang JW
    Zhonghua Zhong Liu Za Zhi; 2018 May; 40(5):384-389. PubMed ID: 29860767
    [No Abstract]   [Full Text] [Related]  

  • 9. Dynamic microbubble contrast-enhanced US to measure tumor response to targeted therapy: a proposed clinical protocol with results from renal cell carcinoma patients receiving antiangiogenic therapy.
    Williams R; Hudson JM; Lloyd BA; Sureshkumar AR; Lueck G; Milot L; Atri M; Bjarnason GA; Burns PN
    Radiology; 2011 Aug; 260(2):581-90. PubMed ID: 21555352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dynamic Contrast-Enhanced Computed Tomography-Derived Blood Volume and Blood Flow Correlate With Patient Outcome in Metastatic Renal Cell Carcinoma.
    Mains JR; Donskov F; Pedersen EM; Madsen HH; Rasmussen F
    Invest Radiol; 2017 Feb; 52(2):103-110. PubMed ID: 27513367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
    Grünwald V; Lin X; Kalanovic D; Simantov R
    Eur Urol; 2016 Dec; 70(6):1006-1015. PubMed ID: 27238653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of response to anti-angiogenic targeted therapy in pulmonary metastatic renal cell carcinoma: R2* value as a predictive biomarker.
    Wu G; Liu G; Kong W; Qu J; Suo S; Liu X; Xu J; Zhang J
    Eur Radiol; 2017 Sep; 27(9):3574-3582. PubMed ID: 28130612
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of progression-free survival as a surrogate end-point for overall survival in patients with metastatic renal cell carcinoma.
    Négrier S; Bushmakin AG; Cappelleri JC; Korytowsky B; Sandin R; Charbonneau C; Michaelson MD; Figlin RA; Motzer RJ
    Eur J Cancer; 2014 Jul; 50(10):1766-1771. PubMed ID: 24768571
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dynamic biomarker and imaging changes from a phase II study of pre- and post-surgical sunitinib.
    Welsh SJ; Thompson N; Warren A; Priest AN; Barrett T; Ursprung S; Gallagher FA; Zaccagna F; Stewart GD; Fife KM; Matakidou A; Machin AJ; Qian W; Ingleson V; Mullin J; Riddick ACP; Armitage JN; Connolly S; Eisen TGQ
    BJU Int; 2022 Aug; 130(2):244-253. PubMed ID: 34549873
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Significance of preoperative prognostic nutrition index as prognostic predictors in patients with metastatic renal cell carcinoma with tyrosine kinase inhibitors as first-line target therapy.
    Cai W; Zhong H; Kong W; Dong B; Chen Y; Zhou L; Xue W; Huang Y; Zhang J; Huang J
    Int Urol Nephrol; 2017 Nov; 49(11):1955-1963. PubMed ID: 28889323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The association of pre-treatment neutrophil to lymphocyte ratio with response rate, progression free survival and overall survival of patients treated with sunitinib for metastatic renal cell carcinoma.
    Keizman D; Ish-Shalom M; Huang P; Eisenberger MA; Pili R; Hammers H; Carducci MA
    Eur J Cancer; 2012 Jan; 48(2):202-8. PubMed ID: 22018713
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Utilizing pre-therapy clinical schema and initial CT changes to predict progression-free survival in patients with metastatic renal cell carcinoma on VEGF-targeted therapy: a preliminary analysis.
    Smith AD; Shah SN; Rini BI; Lieber ML; Remer EM
    Urol Oncol; 2013 Oct; 31(7):1283-91. PubMed ID: 21956044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sunitinib-induced hypertension, neutropaenia and thrombocytopaenia as predictors of good prognosis in patients with metastatic renal cell carcinoma.
    Rautiola J; Donskov F; Peltola K; Joensuu H; Bono P
    BJU Int; 2016 Jan; 117(1):110-7. PubMed ID: 25252180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hypertension and angiotensin system inhibitors: impact on outcome in sunitinib-treated patients for metastatic renal cell carcinoma.
    Izzedine H; Derosa L; Le Teuff G; Albiges L; Escudier B
    Ann Oncol; 2015 Jun; 26(6):1128-1133. PubMed ID: 25795198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib.
    Rini BI; Cohen DP; Lu DR; Chen I; Hariharan S; Gore ME; Figlin RA; Baum MS; Motzer RJ
    J Natl Cancer Inst; 2011 May; 103(9):763-73. PubMed ID: 21527770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.